Skip to main content
. 2012 Feb;73(1-2):65–84. doi: 10.1016/j.curtheres.2012.02.004

Figure 1.

Figure 1

Design of (A) TEAMSTA-5 and TEAMSTA-5 Follow-Up and (B) TEAMSTA-10 and TEAMSTA-10 Follow-Up studies evaluating the safety and efficacy of telmisartan 40 mg/amlodipine 5 mg (T40/A5), telmisartan 80 mg/amlodipine 5 mg (T80/A5), telmisartan 40 mg/amlodipine 10 mg (T40/A10), and telmisartan 80 mg/amlodipine 10 mg (T80/A10) single-pill combinations with or without additional antihypertensive medication (add-on). E= enrollment; R = randomization; T = treatment. *Patients could only be randomized if diastolic blood pressure (DBP) was not adequately controlled after 6 weeks of A5 or A10 monotherapy (ie, DBP ≥90 mm Hg); †At these visits, patients were uptitrated to T80/A5 or T80/A10 if DBP ≥90 mm Hg (ie, response-driven titration); ‡Add-on therapy could be given if trough DBP ≥90 mm Hg.